15 Jan StemSight
Posted at 20:49h
in
Laura Koivusalo, CEO and Founder
April 28 | 5:15pm | Salone dei Cavalieri, Section 1
Tampere, Finland
(Private)
StemSight develops off-the-shelf stem cell therapies for curing blindness. Based out of Tampere, Finland, StemSIght is backed by 20+ years of academic research on pluripotent stem cells for ocular applications. StemSight’s go-to-market is a rare disease called limbal stem cell deficiency (LSCD), a severe and currently untreatable corneal disease, with an orphan drug fast-track to market and a well-established clinical rationale for the cell therapy approach. StemSight’s lead asset is currently in preclinical stage, with first-in-human trials planned for 2028.
